Related Experiment Video
Updated: Apr 18, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antithrombotic therapy in diabetic patients with coronary artery disease
G Lemesle1, A Bauters, C Bauters
1Centre Hospitalier Régional et Universitaire de Lille, Lille, France - christophe.bauters@chru-lille.fr.
Insights
Diabetic patients with coronary artery disease (CAD) face higher risks. Newer antithrombotics like prasugrel and ticagrelor show promise, but bleeding risks require careful management.
Area of Science:
- Cardiology
- Diabetology
- Pharmacology
Background:
- Diabetic patients with coronary artery disease (CAD) have increased risks of ischemic events.
- They exhibit a pro-thrombotic state and reduced responsiveness to antiplatelet agents like aspirin and clopidogrel.
- Balancing antithrombotic benefits against bleeding risks is crucial in this population.
Purpose of the Study:
- To review the role and efficacy of antithrombotic therapies in diabetic patients with CAD.
- To discuss the challenges posed by impaired drug response and increased bleeding risk.
- To evaluate current and emerging antithrombotic strategies for diabetic CAD patients.
Main Methods:
- Literature review of studies on antithrombotic treatments in diabetic CAD patients.
- Analysis of clinical trial data comparing different antiplatelet agents and anticoagulation strategies.
- Assessment of the benefit-risk profiles of various antithrombotic regimens.
Main Results:
- Newer P2Y12 inhibitors (prasugrel, ticagrelor) combined with aspirin offer superior efficacy in acute coronary syndromes for diabetic patients.
- In stable CAD, aspirin monotherapy remains standard, but enhanced strategies are under investigation.
- Combining anticoagulation with antiplatelet therapy significantly increases bleeding risk and requires cautious, limited use.
Conclusions:
- Personalized antithrombotic strategies are essential for diabetic CAD patients, considering their unique pathophysiology.
- While newer agents improve outcomes in acute settings, careful monitoring for bleeding is paramount.
- Further research is needed to optimize long-term antithrombotic management in this high-risk group.
Abstract:
In case of coronary artery disease (CAD), diabetic patients are at higher risk than their non-diabetic counterparts. Antithrombotics are therefore of key importance to decrease the risk of ischemic complications. A careful assessment of the benefit-risk balance is however needed to limit the risk of bleeding. Diabetic CAD patients are characterized by a pro-thrombotic milieu and by an impaired response to both aspirin and P2Y12 receptor inhibitors, especially to clopidogrel. When combined with aspirin, the new P2Y12 receptor inhibitors prasugrel and ticagrelor provide superior efficacy for the diabetic patients with acute coronary syndromes. In stable CAD, antiplatelet monotherapy (aspirin) remains for the time being the reference treatment for diabetic as well as for non-diabetic patients; further studies are however ongoing to test whether the antithrombotic strategy should be reinforced, particularly in case of diabetes mellitus. Finally, although chronic oral anticoagulation is rarely indicated for CAD management in itself, it is often prescribed for the concomitant treatment of atrial fibrillation. The combination of anticoagulation and antiplatelet therapy is associated with a high risk of bleeding and should only be prescribed for limited periods of time when the estimated benefits exceed the risks.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management